About Senti Biosciences, Inc. - Common Stock (SNTI)
Senti Biosciences, Inc. is a biotechnology company focused on developing innovative cell and gene therapies using its proprietary platform to enhance the therapeutic potential of engineered cells. The company utilizes advanced synthetic biology techniques to create intelligent and programmable therapies designed to target specific diseases with greater precision. By harnessing the power of genetic engineering, Senti aims to address unmet medical needs, particularly in the areas of cancer and other serious conditions, ultimately improving patient outcomes through its cutting-edge research and development initiatives. Read More
Senti Biosciences shares are trading higher by 102.6% during Monday's session. The company was awarded $8 million from the California Institute for Regenerative Medicines.
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 –
